Yuma Wada1,2,3, Mitsuo Shimada2, Kensuke Yamamura1,4, Takeo Toshima5, Jasjit K Banwait1, Yuji Morine2, Tetsuya Ikemoto2, Yu Saito2, Hideo Baba4, Masaki Mori5, Ajay Goel1,3. 1. Center for Gastrointestinal Research, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX. 2. Department of Surgery, Tokushima University, Tokushima, Japan. 3. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA. 4. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. 5. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND AND AIMS: Tumor recurrence is frequent even in intrahepatic cholangiocarcinoma (ICC), and improved strategies are needed to identify patients at highest risk for such recurrence. We performed genome-wide expression profile analyses to discover and validate a gene signature associated with recurrence in patients with ICC. APPROACH AND RESULTS: For biomarker discovery, we analyzed genome-wide transcriptomic profiling in ICC tumors from two public data sets: The Cancer Genome Atlas (n = 27) and GSE107943 (n = 28). We identified an eight-gene panel (BIRC5 [baculoviral IAP repeat containing 5], CDC20 [cell division cycle 20], CDH2 [cadherin 2], CENPW [centromere protein W], JPH1 [junctophilin 1], MAD2L1 [mitotic arrest deficient 2 like 1], NEIL3 [Nei like DNA glycosylase 3], and POC1A [POC1 centriolar protein A]) that robustly identified patients with recurrence in the discovery (AUC = 0.92) and in silico validation cohorts (AUC = 0.91). We next analyzed 241 specimens from patients with ICC (training cohort, n = 64; validation cohort, n = 177), followed by Cox proportional hazard regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model for recurrence in ICC. We subsequently trained this transcriptomic panel in a clinical cohort (AUC = 0.89; 95% confidence interval [CI] = 0.79-0.95), followed by evaluating its performance in an independent validation cohort (AUC = 0.86; 95% CI = 0.80-0.90). By combining our transcriptomic panel with various clinicopathologic features, we established a risk-stratification model that was significantly superior for the identification of recurrence (AUC = 0.89; univariate HR = 6.08, 95% CI = 3.55-10.41, P < 0.01; and multivariate HR = 3.49, 95% CI = 1.81-6.71, P < 0.01). The risk-stratification model identified potential recurrence in 85% of high-risk patients and nonrecurrence in 76% of low-risk patients, which is dramatically superior to currently used pathological features. CONCLUSIONS: We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC.
BACKGROUND AND AIMS: Tumor recurrence is frequent even in intrahepatic cholangiocarcinoma (ICC), and improved strategies are needed to identify patients at highest risk for such recurrence. We performed genome-wide expression profile analyses to discover and validate a gene signature associated with recurrence in patients with ICC. APPROACH AND RESULTS: For biomarker discovery, we analyzed genome-wide transcriptomic profiling in ICC tumors from two public data sets: The Cancer Genome Atlas (n = 27) and GSE107943 (n = 28). We identified an eight-gene panel (BIRC5 [baculoviral IAP repeat containing 5], CDC20 [cell division cycle 20], CDH2 [cadherin 2], CENPW [centromere protein W], JPH1 [junctophilin 1], MAD2L1 [mitotic arrest deficient 2 like 1], NEIL3 [Nei like DNA glycosylase 3], and POC1A [POC1 centriolar protein A]) that robustly identified patients with recurrence in the discovery (AUC = 0.92) and in silico validation cohorts (AUC = 0.91). We next analyzed 241 specimens from patients with ICC (training cohort, n = 64; validation cohort, n = 177), followed by Cox proportional hazard regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model for recurrence in ICC. We subsequently trained this transcriptomic panel in a clinical cohort (AUC = 0.89; 95% confidence interval [CI] = 0.79-0.95), followed by evaluating its performance in an independent validation cohort (AUC = 0.86; 95% CI = 0.80-0.90). By combining our transcriptomic panel with various clinicopathologic features, we established a risk-stratification model that was significantly superior for the identification of recurrence (AUC = 0.89; univariate HR = 6.08, 95% CI = 3.55-10.41, P < 0.01; and multivariate HR = 3.49, 95% CI = 1.81-6.71, P < 0.01). The risk-stratification model identified potential recurrence in 85% of high-risk patients and nonrecurrence in 76% of low-risk patients, which is dramatically superior to currently used pathological features. CONCLUSIONS: We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC.
Authors: Olivier Farges; David Fuks; Yves-Patrice Le Treut; Daniel Azoulay; Alexis Laurent; Philippe Bachellier; Gennaro Nuzzo; Jacques Belghiti; François René Pruvot; Jean Marc Regimbeau Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Elisa Lozano; Rocio I R Macias; Maria J Monte; Maitane Asensio; Sofia Del Carmen; Laura Sanchez-Vicente; Marta Alonso-Peña; Ruba Al-Abdulla; Patricia Munoz-Garrido; Letizia Satriano; Colm J O'Rourke; Jesus M Banales; Matias A Avila; Maria L Martinez-Chantar; Jesper B Andersen; Oscar Briz; Jose J G Marin Journal: Hepatology Date: 2019-05-20 Impact factor: 17.425
Authors: David M Studdert; Michelle M Mello; William M Sage; Catherine M DesRoches; Jordon Peugh; Kinga Zapert; Troyen A Brennan Journal: JAMA Date: 2005-06-01 Impact factor: 56.272
Authors: Peter J Kneuertz; David P Cosgrove; Andrew M Cameron; Ihab R Kamel; Jean-Francois H Geschwind; Joseph M Herman; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2012-04 Impact factor: 3.452
Authors: Hyungjin Rhee; Jung Eun Ko; Taek Chung; Byul A Jee; So Mee Kwon; Ji Hae Nahm; Jae Yeon Seok; Jeong Eun Yoo; Jin-Sub Choi; Snorri S Thorgeirsson; Jesper B Andersen; Hye Sun Lee; Hyun Goo Woo; Young Nyun Park Journal: Liver Int Date: 2017-07-10 Impact factor: 5.828
Authors: Leticia Colyn; Gloria Alvarez-Sola; M Ujue Latasa; Carmen Berasain; Maite G Fernandez-Barrena; Matias A Avila; Iker Uriarte; Jose M Herranz; Maria Arechederra; George Vlachogiannis; Colin Rae; Antonio Pineda-Lucena; Andrea Casadei-Gardini; Federica Pedica; Luca Aldrighetti; Angeles López-López; Angeles López-Gonzálvez; Coral Barbas; Sergio Ciordia; Sebastiaan M Van Liempd; Juan M Falcón-Pérez; Jesus Urman; Bruno Sangro; Silve Vicent; Maria J Iraburu; Felipe Prosper; Leonard J Nelson; Jesus M Banales; Maria Luz Martinez-Chantar; Jose J G Marin; Chiara Braconi; Christian Trautwein; Fernando J Corrales; F Javier Cubero Journal: J Exp Clin Cancer Res Date: 2022-05-26